Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
256,606,920
-
Number of holders
-
605
-
Total 13F shares, excl. options
-
237,711,534
-
Shares change
-
+1,940,860
-
Total reported value, excl. options
-
$36,110,677,595
-
Value change
-
+$313,167,858
-
Put/Call ratio
-
74.8%
-
Number of buys
-
339
-
Number of sells
-
-221
-
Price
-
$152.04
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q3 2017
685 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q3 2017.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 605 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 237,711,534 shares
of 256,606,920 outstanding shares and own 92.6% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (26,478,714 shares), BlackRock Inc. (19,735,921 shares), VANGUARD GROUP INC (17,612,047 shares), FMR LLC (16,560,445 shares), WELLINGTON MANAGEMENT GROUP LLP (13,267,346 shares), Capital World Investors (11,561,841 shares), STATE STREET CORP (11,218,527 shares), JPMORGAN CHASE & CO (9,322,447 shares), Clearbridge Investments, LLC (7,080,171 shares), and JENNISON ASSOCIATES LLC (6,017,766 shares).
This table shows the top 605 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.